Redeye initiates coverage of Senzime, a Swedish medtech company specialising in quantitative neuromuscular patient monitoring with its flagship device, the TetraGraph system. With a rapidly expanding installed base and rising utilisation rates, we see a compelling growth trajectory ahead. Our fair value range indicates solid upside potential, with quarterly reports demonstrating solid growth as the primary trigger for the share price.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/